LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood MicroRNA Biomarker Distinguishes Myocarditis from Myocardial Infarction

By LabMedica International staff writers
Posted on 08 Jun 2021
Print article
Image: First biomarker in blood that distinguishes myocarditis from an acute myocardial infarction (Photo courtesy of Centro Nacional De Investigaciones Cardiovasculares)
Image: First biomarker in blood that distinguishes myocarditis from an acute myocardial infarction (Photo courtesy of Centro Nacional De Investigaciones Cardiovasculares)
A novel microRNA has been found that can be used to distinguish patients with myocarditis from those with myocardial infarction.

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Myocarditis is usually diagnosed after coronary angiography or computed tomography scans have ruled out coronary artery disease, followed by confirmation of the diagnosis by magnetic resonance imaging (MRI). However, not all centers have access to MRI technology, and the current gold standard for myocarditis diagnosis is endomyocardial biopsy, an invasive procedure normally reserved for severe cases. Thus a pressing clinical need exists for the development of reliable and accessible tools for the early diagnosis of acute myocarditis.

In this regard, investigators at the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain) and their collaborators in Spain and abroad sought to identify a novel microRNA for the diagnosis of acute myocarditis.

To identify a microRNA specific for myocarditis, they performed microRNA microarray analyses and quantitative polymerase-chain-reaction (qPCR) assays in sorted CD4+ T cells and type 17 helper T (Th17) cells after inducing experimental autoimmune myocarditis or myocardial infarction in mice. They then identified the human homologue for this microRNA and compared its expression in plasma obtained from patients with acute myocarditis with the expression in various controls.

Results revealed that the human homologue, designated hsa-miR-Chr8:96, could be identified in four independent cohorts of patients with myocarditis. The area under the receiver-operating-characteristic curve for this novel microRNA for distinguishing patients with acute myocarditis from those with myocardial infarction was 0.927. The microRNA retained its diagnostic value in models after adjustment for age, sex, ejection fraction, and serum troponin level.

"Our finding has great potential as a valuable clinical tool for the precise and noninvasive diagnosis of myocarditis from small drops of blood," said senior author Dr. Pilar Martín, a research professor at the Centro Nacional de Investigaciones Cardiovasculares.

The myocarditis paper was published in the May 27, 2021, online edition of The New England Journal of Medicine.

Related Links:
Centro Nacional de Investigaciones Cardiovasculares

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more